Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNS01-T
- Development stage
- Phase 2
- Lead developer
- Sevion Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**SNS01-T** is an investigational, intravenously administered polyethylenimine nanoparticle developed for relapsed or refractory B-cell malignancies. It co-delivers a B-cell-promoter-driven plasmid encoding the non-hypusinable, pro-apoptotic eIF5A K50R mutant and an siRNA that suppresses endogenous eukaryotic translation initiation factor 5A expression. The intended dual mechanism is depletion of pro-survival hypusinated eIF5A while expression of eIF5A K50R promotes apoptosis in malignant B cells. It entered a Phase 1/2 dose-escalation study in multiple myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma, other B-cell lymphoma, and plasma cell leukemia; the sponsor subsequently placed the clinical program on hold. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24569836/))
- Other names
- SNS-01-TSNS01-TSNS 01-TSNS01SNS-01SNS 01
02
Targets
EIF5A (Eukaryotic translation initiation factor 5A)EIF5A K50R (Eukaryotic translation initiation factor 5A K50R mutant)
Beyond the preview
Go deeper on SNS01-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNS01-T.